RxDoctor Payments Data

Christine Phillips, MD

Rheumatology · Hanover, PANPI 1346257045

Payments from drug & device makers

$5,747in general payments, 2019–2025

Across 72 payments — averaging $79.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$1K
  • Amgen$882
  • Novartis$402
  • UCB, Inc.$164
  • Pfizer$141
  • plus $535 from 8 others

What the payments were for

  • Consulting fees$2,00036%
  • Food & beverage$3,03455%
  • Education$4588%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,747 in reported general payments places this provider in the 55th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$155,189
Medicare patients
537
Services billed
2,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept54$401,153
OtezlaApremilast39$204,058
Enbrel MiniEtanercept17$180,614
Xeljanz XrTofacitinib Citrate11$60,776
Actemra ActpenTocilizumab16$53,261
Hydroxychloroquine Sulfate938$52,231
Teriparatide14$43,278
SavellaMilnacipran Hcl34$25,129
Celecoxib367$14,046
MethotrexateMethotrexate Sodium516$13,835
Nabumetone547$10,144
Febuxostat85$8,765
Duloxetine Hcl417$6,995
Leflunomide46$4,576
Cevimeline Hcl16$3,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$882$204,05839 claims
AbbVieSavella$1,143$25,12934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →